Kornimate/medical-research-clean huggingface dataset:
cognitive impairment cohort study of the elderly population in yugarden

Conditions: Alzheimer Disease; Neurodegenerative Diseases; Cognitive Impairment; Mild Cognitive Impairment

Summary: the goal of this prospective observational research with an 8-year follow-up is to study the cognitive changes in the elderly in yugarden community, shanghai, china. the main questions it aims to answer are: * incidence of cognitive impairment in community (converting to mild cognitive impairment or alzheimer's disease) * to build a predictive model for the progression of cognitive impairment

this study is a prospective observational study which involves a large sample cohort of the elderly aged 60 to 85 years in yugarden community, shanghai, china, with an 8-year follow-up. demographic information, peripheral organs evaluation (facial expression, hearing, oct angiography), cognitive tests (mmse, adl), biospecimen (peripheral blood, urine, feces, gingival crevicular fluid), speech information, neuroimaging (mri, pet) and electroencephalogram (eeg) will be collected and analyzed. follow-up visits will be conducted twice a year for 4 visits and each visit includes cognitive tests, biospecimen collection, speech test, mri and eeg. the primary outcome is the incidence of cognitive impairment indicating people who convert to mild cognitive impairment (mci) or alzheimer's disease (ad). furthermore, a predictive model for the progression of cognitive impairment will be constructed.

Eligibility criteria:
inclusion criteria: 1. the participants are community-dwelling elderly people living in yuyuan community, shanghai, aged 60-85 years old, with no gender restriction. 2. non-ad patients. 3. the participants can complete the cognitive tests, biological sample collection, speech tests, neuroimaging examinations, and cooperate with the implementation of the whole process of research. 4. the participants agree to participate in this study and sign the informed consent form. exclusion criteria: 1. participants who are suffering from severe mental illness, tumor cachexia, severe liver and kidney dysfunction and other serious physical diseases and unable to cooperate with the examination. 2. participants who have visual or auditory impairment that hampers the completion of related examination. 3. situations when magnetic resonance imaging or other examinations are contraindicated.

Keywords: alzheimer disease mild cognitive impairment cohort
second survey of intensive care in india

Conditions: Critical Illness

Summary: indicaps was the first large scale, multicentre survey launched by the isccm. the aim was to gather information about icus, organizational characteristics, patient casemix, the types and severity of illness, monitoring and therapeutic modalities used, types of infections, and other such data. this was performed between july 2010 and april 2011 and published in 2016.\[1\] over the last 8 years, there has been a significant difference in the delivery of intensive care services, critical care education, socioeconomic indicators, antibiotic resistance patterns and other aspects of practices in indian icus. it is therefore necessary to revisit and resurvey the current trends in intensive care practices in india, and to reflect the vast spectrum of critical care illness, services and practices. similar to indicaps, which was a point-prevalence study of all patients present in the icu on four different days over a one-year period, indicaps ii will record data of all patients admitted to the icu on 4 different days.

indicaps ii will record data of all patients admitted to the icu on 4 different days (august 23, 2018; october 25, 2018; december 13, 2018; april 11, 2019) in a cross-sectional design. data collection includes: 1. on admission: demographic characteristics, comorbidities, source of admission, primary and secondary admission diagnoses, 2. baseline data (on the study day), including parameters used to calculate saps ii score and sofa score and infections, 3. information on monitoring modalities, mechanical ventilation, nutrition, fluid therapy, other routine icu practices c. outcome at icu and hospital discharge d. organisation of icu services

Eligibility criteria:
inclusion criteria: * all patients present in the icu on august 23, 2018; october 25, 2018; december 13, 2018; april 11, 2019 exclusion criteria: * none

Keywords: critical care unit
effect of right ventricular lead position on defibrillation threshold

Conditions: Ventricular Tachycardia; Ventricular Fibrillation

Summary: the purpose of this study is to determine how the position of the right ventricular (rv) coil of an implantable cardioverter defibrillator (apex versus septum) affects the defibrillation threshold; specifically, can defibrillator threshold be improved by implantation site selection.

the investigators propose a prospective, pseudo-randomized study of patients who are electing to undergo implantation of an implantable cardioverter defibrillator (icd). there are two locations in the heart in which icds are normally implanted: the apex and the septum. the purpose of this study is to determine whether the icd performs better in one location or the other, as measured by defibrillation threshold. in this study, both locations will be tested in each patient. the final location will be determined by the implanting physician as the location that is best for the patient.

Eligibility criteria:
inclusion criteria: * patient indicates for single-chamber (vr), dual-chamber (dr) or resynchronization crt-d) implantable defibrillator * left-sided implant * single coil or dual coil (single coil for testing) * age ≥ 18 years of age * ability to consent * medically stable, in the opinion of the implanting physician, to undergo defibrillation safety margin testing * procedure performed under conscious sedation * english-speaking exclusion criteria: * patient unable to understand and consent to the procedure on his or her own * pregnant or breastfeeding patients * new york heart association (nyha) class iv * patients with pre-existing rv leads * pacemaker dependent * patient medically unstable to undergo defibrillation testing (e.g., high risk for deep sedation; patients that develop respiratory compromise or hemodynamic instability from the sedation) * patients that require general anesthesia instead of conscious sedation * patients \<18 years of age * non-english-speaking
evaluating the impact of cerebral ischemic and degenerative changes on cognition

Conditions: Cognitive Decline

Summary: the purpose of this study is to evaluate whether or not cerebral atrophy scores obtained from a brain mri can correlate with cognitive test results. these results hope to demonstrate a link between cerebral ischemic/degenerative changes shown on the mri and cognition functions results.

preliminary evidence indicates that intracranial atherosclerosis may predict incident cerebrovascular events and central atrophy. age induced changes on cerebral tissue in adulthood is witnessed as atrophy and well know ischemic changes on imaging studies. there is no consensus at this time what constitutes normal, age induced atrophy and pathologic atrophy on imaging studies. the same challenge is also encountered for ischemic cerebral parenchymal change. until recently there have been several important limitations in this research 1) measurement of cerebral tissue loss and amount of ischemic insult was based on a qualitative grading (2) there was no cognitive testing. with advancements in software technology that have now allowed for measurements of csf and brain volumes in reliable and reproducible ways and the neuroradiologist having access to the subject's neurological cognitive testing scores, this study will objectively measure mri findings and correlate them with the level of cognitive function. this study will look at subjects who have undergone cognitive testing from the neurology clinic and then referred for an mri brain exam, as standard of care testing. the mri information will be acquired by volumetric technique for calculation of brain and csf volumes and mri data will be plotted against the cognitive test results. the results of this study will be to correlate quantitative measures of cerebral atrophic and ischemic changes with level of cognition and to establish reliable imaging criteria that can help identify normal, age induced versus pathologic. information obtained will shed light to cognitive effects and imaging appearance of: separation of normal age related changes from pathologic states, changes leading to dementia and normal pressure hydrocephalus.

Eligibility criteria:
inclusion criteria: * subjects older than 50 years of age * subjects who have undergone cognitive testing * subjects who can cooperate and give informed consent exclusion criteria: * subjects with known medical conditions predisposing them for atrophy such as: chronic renal failure, hiv, head/neck tumors, prior radiation, post- traumatic brain disorder, metabolic disorders of brain, polysubstance abuse, and steroid use

Keywords: cognitive functions brain ischemia cerebral atrophy dementia intracranial atherosclerosis memory impairment
study on glucocorticoid combined with gamma globulin and ropristine n01 in treatment of initial severe itp

Conditions: Primary Immune Thrombocytopenia

Summary: the goal of this clinical trial is to learn if romiplostim n01 works to treat severe primary immune thrombocytopenia in adults. it will also learn about the safety of romiplostim n01. the main question it aims to answer is: to evaluate the effectiveness of the combination treatment of glucocorticoids, gamma globulin and romiplostim n01 in patients with severe primary immune thrombocytopenia during the initial treatment period for one month. participants will: romiplostim n01, starting dose of 1 µg/kg, subcutaneous injection, given on the third day of ivig, once a week, for up to one month. ivig, 400mg/kg/d, intravenous administration, continuous administration for 3-5 days. prednisone, 0.8mg/kg/d, taken orally or intravenously, for up to one month.


Eligibility criteria:
inclusion criteria: 1. participants must sign a written informed consent prior to enrollment; 2. ages 18-75; 3. platelet count \<10×10\^9/l with active bleeding or bleeding score ≥5; 4. no contraindications to the use of steroids, romiplostim, or ivig, and willingness to receive these treatments; 5. no prior splenectomy or at least one first-line itp treatment or emergency treatment; 6. no prior romiplostim treatment; 7. ecog ps score: 0-2; 8. female participants of childbearing potential must agree to use reliable contraception (including male or female condoms, contraceptive foam, contraceptive jelly, contraceptive patches, contraceptive cream, contraceptive suppositories, abstinence, and placement of intrauterine contraceptive devices) throughout the study; women who have had a hysterectomy, bilateral oophorectomy, bilateral salpingo-oophorectomy, or have been postmenopausal for more than 1 year, and men who have had bilateral vasectomy or vasectomy are excluded; 9. voluntary participation in this study and good compliance. exclusion criteria: 1. individuals with the following hematological disorders other than itp, including but not limited to leukemia, thrombocytopenia caused by cancer treatment, myeloproliferative diseases, multiple myeloma, and myelodysplastic syndrome; 2. individuals with a history of thrombosis; 3. pregnant or lactating individuals; 4. individuals with severe cardiopulmonary insufficiency; 5. individuals with severe or uncontrollable infections; 6. individuals with viral infections; 7. individuals who cannot comply due to psychological reasons; 8. individuals who are deemed unsuitable for participation in the study by the investigator.

Keywords: severe itp romiplostim
safety and efficacy of mcg for diagnosing coronary heart disease

Conditions: Myocardial Ischemia

Summary: a magnetocardiograph (mcg) is a medical device capable of recording the magnetic fields that arise from the electrical activity of the heart. it was developed for the general purpose as a noninvasive, non-contact diagnostic tool of obstructive coronary artery disease (cad), and especially of cardiac ischemia. the overall objective of the present study is to demonstrate the efficacy of this mcg device in the diagnosis of lack of oxygen to an area of the heart (as in an heart attack) in patients presenting with chest pain.

the cmi-2409 magnetocardiograph (mcg) is an fda-approved medical device capable of noninvasive recording of magnetic fields arising from the electrical activity of the heart. this system was developed by cmi for the general purpose of noninvasive, non-contact diagnostics of obstructive coronary artery disease (cad), and especially of cardiac ischemia. the overall objective of the present study is to demonstrate the efficacy of this mcg device and of the associated mcg method for the detection and diagnosis of ischemia in chest pain patients. the primary objective is to demonstrate that the diagnostic accuracy of the mcg device and method is equivalent to or better than that of a standard 12-lead ecg for detecting the presence of ischemia in patients presenting with chest pain of unknown etiology. in this study the rest mcg data will be analyzed and compared to the results of a rest ecg.

Eligibility criteria:
subjects with chest pain syndrome or angina equivalent
perception of symptom variability in copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the objective of the study is to assess patient's perception with stable state copd on symptom variability and to describe how symptom variability impacts daily quality of life in chinese copd patient with moderate, severe or very severe airflow limitation from tier 3 hospitals in china where most of copd patients are diagnosed and treated.


Eligibility criteria:
inclusion criteria: * provision of subject informed consent * out-patient * clinical diagnosis of copd at least 6 months * lung function based on data available within 3 months in medical records confirming fev1\<80% normal predicted (post-bronchodilator) and fev1/fvc\<0.7 (post-bronchodilator) exclusion criteria: * participation in any interventional study involving investigational drugs; patient inability to understand the study procedures or inability/reluctance to answer questionnaire * ongoing exacerbation of copd or exacerbation within the previous 3 months. an exacerbation is defined as a worsening of copd symptoms leading to a treatment with antibiotics and/or a short course of system steroids and/or hospitalisation or emergency * history of asthma and/or allergic rhinitis, lung cancer or any other significant respiratory disease such as bronchiectasis, lung fibrosis, interstitial lung disease, tuberculosis, sarcoidosis

Keywords: copd, symptoms, non-interventional study,
evaluation of anatomy, clinical and neuropsychological long-term sequelae of patients treated with radiation therapy for brain tumor

Conditions: Brain Neoplasms

Summary: through this study, the investigators believe to describe more accurately the damage caused by brain radiation therapy in the long term.


Eligibility criteria:
inclusion criteria: in the case group: * a history of solid brain tumor or haematological histologically proven. * patients previously treated with radiotherapy in this brain tumor (greater than or equal to 36 gy dose). * radiotherapy treatment on a tumor in place or operated. * decline at least 10 years from the end of radiotherapy. * treatment with isocentric conformal radiotherapy. * no other radiation therapy for locally recurrent brain metastases or new brain tumor. * lack of known brain metastases or meningeal carcinomatosis. for the control group: * patients previously treated for cancer and disease relapse free for 10 years. * no brain radiotherapy treatment. * lack of treatment with anti-cancer chemotherapy. * women of childbearing potential must be under effective contraception. * pairing according to age, sex, arms director and socio-cultural level. for two groups: * man or woman aged (e) of minimum 18 years. * topic fluent french and comprising well. * free and informed consent signed. * the subject should be affiliated to an appropriate social security system * no cons-indication to mri. * the subject must have at least one primary school level exclusion criteria: in the case group: * brain radiotherapy carried out by intensity modulation technique. * radiation dose less than 36 gy on the brain. * subject with against-indication to mri. for the control group: * previous history of brain radiotherapy. * previous history of brain surgery. * central neurological disorders, such as seizures, uncontrolled. for two groups: * current topics in oral chemotherapy or intravenous. * subject pregnant. * subject is not fluent in french or including bad. * any geographical conditions, social or associated psychopathology that could compromise the patient's ability to participate in the study. * participation in a therapeutic trial for less than 30 days. * a person not affiliated with a social security scheme.

Keywords: brain radiotherapy mri sequelae
pre-hospital advanced therapies for control of hemorrhage - pelvis

Conditions: Hemorrhage; Pelvic Fracture

Summary: the purpose of this study is to determine whether the use of pelvic binders in the ambulance setting improves outcomes including mortality in patients with pelvic fractures.

the goal of this prospective, randomized clinical trial is to determine whether prehospital use of a commercial pelvic binder will improve morbidity and mortality in patients with pelvic fractures. we hypothesize that prehospital placement of pelvic binders will reduce hemorrhage and need for resuscitation and will improve overall mortality in patients with pelvic fractures. in addition, we hypothesize that pelvic splinting via external compression will improve patients' pain regardless of whether they have a pelvic, acetabular, or proximal femur fracture.

Eligibility criteria:
inclusion criteria: * traumatic injury other than ground-level fall, and * complaint of pelvic groin or hip pain, or * pelvic or hip deformity, ecchymosis, or crepitus in an obtunded patient, or * hemodynamic instability exclusion criteria: * ground level fall * penetrating pelvis injury without frank evidence of fracture * obviously pregnant patients * patients who are too small or too big for the binder * priority 2 or 3 trauma
drug-related problems in neonatal patients

Conditions: Neonatal Intensive Care Unit; Medication Errors; Drug-Related Problems; Adverse Drug Event; Drug-Drug Interaction; Clinical Pharmacy; Machine Learning

Summary: drug-related problems in newborn babies have been reported with a rate of 4-30%. it is estimated that the higher rates of these problems in hospitalized children under the age of two are related to the variety of drugs used and the differences in the age, weight and diagnosis of the patients. in this context, with the clinical parameters and demographic data obtained in the first 24 hours of the patients hospitalized in the neonatal intensive care unit, machine learning algorithms are used to predict the risks that may arise from possible drug-related problems (prescribing and administration errors, side effects and drug-drug interactions) that may occur during hospitalization. the algorithm, which will be created by modeling with a high number of big data pool, is planned to be transformed into a clinical decision support system software that can be used easily in clinical practice with online and mobile applications. by processing the data of the patients to be included in the model, it is aimed to prevent and manage drug-related problems before they occur, as well as to provide cost-effective medşcation treatment to patients hospitalized in the neonatal intensive care unit, together with a reduction in the risk of drug-related mortality and morbidity.


Eligibility criteria:
inclusion criteria: * newborns aged 0-28 days, * consent form taken by the parents to participate in the study, * patients admitted to neonatal intensive care unit or surgical wards exclusion criteria: * have a postnatal age greater than 28 days, * patients who will not be given any medication, * patients who took part in any drug research within the last 28 days
fapi-pet imaging of in vivo fibrosis in inflammatory bowel disease patients

Conditions: IBD (Inflammatory Bowel Disease); Crohn Disease (CD); Ulcerative Colitis (UC)

Summary: our main objective is to evaluate the feasibility of 68ga-fapi pet/ct in detecting intestinal fibrosis in patients with ibd. to this end, we will determine 68ga-fapi uptake in ibd in relation to cellular fap expression in intestinal biopsies and resection specimens.


Eligibility criteria:
inclusion criteria: group 1 - adults ≥18 years with confirmed diagnosis of crohn's disease and one of the following: * gastrointestinal complaints such as diarrhea, bloody and/ or lose stools and abdominal pain, or obstructive symptoms. * increased crp (\&gt;5 mg/l) and/or fecal calprotectin levels (\&gt;250 mg/kg) * active disease confiremed by endoscopy ( endoscopic ses-cd score \&gt;3) * active disease confirmed by ius or mri (bowel wall thickening, signs of active disease) group 2 * adults ≥18 years with confirmed diagnosis of ulcerative colitis and one of the following: * active disease confirmed by endoscopy (endoscopic mayo score ≥ 2) or * active disease confirmed by intestinal ultrasound (bwt \&gt; 3 mm in atleast one bowel segment and atleast one other pathological ius parameter) * increased crp (\&gt;5 mg/l) and/or fecal calprotectin levels (\&gt;250 mg/kg) exclusion criteria: * pregnancy * unable to provide informed consent * ibd-related surgeries \&lt; 5 years in medical history * colorectal carcinoma

Keywords: fapi fibroblast activation protein fap fapi-scan 68ga-fapi pet-ct
dietary nitrate and erectile dysfunction

Conditions: Erectile Dysfunction

Summary: an expanding number of studies suggest a therapeutic role for nitrate and nitrite, most notably in treatment and prevention of cardiovascular disease including ischemia-reperfusion injury and hypertension. the nutritional aspects of these cardioprotective effects are particularly intriguing since nitrate is abundant in our everyday diet. nitrate improves vascular functions in old adults and improves ischemia reperfusion injury in experimental models. whether dietary nitrate improves erectile dysfunction is not known and will be investigated in the present study.


Eligibility criteria:
inclusion criteria: patients with erectile dysfunction (iief5: 8-21) pde-5 inhibitors responder aged 30-80 years exclusion criteria: * spinal cord disease * insulin dependent diabetes mellitus * prostate cancer after operation, radiotherapy and hormone therapy * treatment with no-donators or sgc-activators * chronic kidney disease (stage iv-v) * advanced liver dysfunction
the study of efficacy and mechanism in fecal microbiota transplantation in the treatment of ulcerative colitis

Conditions: Ulcerative Colitis; Fecal Microbiota Transplantation

Summary: the aim of our study is to investigate the efficacy and mechanism in fecal microbiota transplantation in the treatment of ulcerative colitis. about 20 ulcerative colitis (uc) patients will be recruited into our trial for fecal microbiota transplantation (fmt) treatment,the safety and efficacy of fmt will be observed.


Eligibility criteria:
inclusion criteria: * mild to moderate uc patients * male * volunteered to our fmt trial exclusion criteria: * severe uc * hb \< 6g/dl